MX2022000429A - Telmisartan para el tratamiento de la enfermedad renal cronica en perros. - Google Patents

Telmisartan para el tratamiento de la enfermedad renal cronica en perros.

Info

Publication number
MX2022000429A
MX2022000429A MX2022000429A MX2022000429A MX2022000429A MX 2022000429 A MX2022000429 A MX 2022000429A MX 2022000429 A MX2022000429 A MX 2022000429A MX 2022000429 A MX2022000429 A MX 2022000429A MX 2022000429 A MX2022000429 A MX 2022000429A
Authority
MX
Mexico
Prior art keywords
telmisartan
treatment
dogs
kidney disease
chronic kidney
Prior art date
Application number
MX2022000429A
Other languages
English (en)
Inventor
Anne Michelle Traas
De Moura Lourenco Bianca Natália Ferreira
Kate Elizabeth Creevy
Scott Alan Brown
Coleman Amanda Erickson
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of MX2022000429A publication Critical patent/MX2022000429A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a telmisartán o una sal farmacéuticamente aceptable del mismo como un medicamento para el tratamiento de niveles elevados de relación de proteína a creatinina en orina (UPC) en los perros, en donde la cantidad terapéuticamente efectiva de telmisartán se administra en una cantidad de dosis diaria que varía durante un período de tratamiento.
MX2022000429A 2019-07-09 2020-04-30 Telmisartan para el tratamiento de la enfermedad renal cronica en perros. MX2022000429A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962871752P 2019-07-09 2019-07-09
PCT/US2020/030579 WO2021006941A1 (en) 2019-07-09 2020-04-30 Telmisartan for the treatment of chronic kidney disease in dogs

Publications (1)

Publication Number Publication Date
MX2022000429A true MX2022000429A (es) 2022-04-25

Family

ID=70775531

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000429A MX2022000429A (es) 2019-07-09 2020-04-30 Telmisartan para el tratamiento de la enfermedad renal cronica en perros.

Country Status (11)

Country Link
US (1) US20220218671A1 (es)
EP (1) EP3996705A1 (es)
JP (1) JP2022540074A (es)
KR (1) KR20220054291A (es)
CN (1) CN114450004A (es)
AU (1) AU2020311280A1 (es)
BR (1) BR112022000315A2 (es)
CA (1) CA3142876A1 (es)
MX (1) MX2022000429A (es)
TW (1) TW202116305A (es)
WO (1) WO2021006941A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7050893B2 (ja) 2017-07-07 2022-04-08 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬

Also Published As

Publication number Publication date
WO2021006941A1 (en) 2021-01-14
US20220218671A1 (en) 2022-07-14
TW202116305A (zh) 2021-05-01
AU2020311280A1 (en) 2022-02-24
CN114450004A (zh) 2022-05-06
JP2022540074A (ja) 2022-09-14
CA3142876A1 (en) 2021-01-14
KR20220054291A (ko) 2022-05-02
EP3996705A1 (en) 2022-05-18
BR112022000315A2 (pt) 2022-02-22

Similar Documents

Publication Publication Date Title
NZ714963A (en) Compositions and methods for treating anemia
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX2019012884A (es) Terapia de combinacion.
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
TW200727905A (en) Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2022000143A (es) Metodos novedosos.
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
MX2022000429A (es) Telmisartan para el tratamiento de la enfermedad renal cronica en perros.
FI3648761T3 (fi) Telmisartaani kissan hypertension ehkäisemiseksi tai hoitamiseksi
MX2023008746A (es) Forma morfica ventajosa de la sal de hemi-sulfato de at-527.
ZA202201446B (en) Methods of treating multifocal cancer
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
MX2022000426A (es) Telmisartan para el tratamiento de la hipertension en perros.
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
EA201590760A1 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции